Question 1

What is LL-37?

Accepted Answer

LL-37 is the one cathelicidin a human body makes, and a 2016 review names it the sole human cathelicidin. Cathelicidins sit inside a wider set of antimicrobial peptides, or AMPs, which are short molecules that go after microbes directly. That review calls them a large family of compounds serving as natural antibiotics, widely distributed across the organism, mainly in mucus layers. A 2007 study of tonsil tissue puts the same idea more plainly, describing antimicrobial cationic peptides as components of the innate immune system. The body builds LL-37 at its own surfaces instead of storing it in a gland: a 2005 study of the eye reported that LL-37/hCAP18 mRNA and LL-37 peptide were expressed by human corneal and conjunctival epithelial cells. The hCAP18 in that sentence is the longer protein that gets cut to release LL-37.

Question 2

Has LL-37 been given to people in published research?

Accepted Answer

No study among the research behind this page gave LL-37 to a person. What the human work does is measure the peptide people are already making, which is a different thing. Skin, tonsil and blood samples were taken, and the amount of LL-37 in them was compared between patients and controls. Two completed entries on the public trial registry follow exactly that pattern. One is listed as Cathelicidin LL-37 Levels in the GCF and the Saliva of Smokers and Non-smokers With Stage III,IV Periodontitis, with 60 people enrolled, where GCF means the fluid that seeps out of the gum pocket. The other is listed as Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis, with 80 enrolled. Both are marked completed and both measured expression. Measuring a molecule in a patient and giving that molecule to a patient are different questions, and only the first one has been asked here.

Question 3

What does the laboratory work actually show?

Accepted Answer

The firmest numbers on LL-37 came out of glassware. A 2005 study put it up against three strains of Pseudomonas aeruginosa and two kinds of staph, and reported that antibacterial activity for LL-37 was demonstrated. Across those five strains the half-effect concentrations ran from 1.3 to 3.6 micrograms per millilitre. A half-effect concentration is simply the amount that gets you halfway to the full result in a test like that one. A 2012 study then asked whether one species answers the same way every time. Across 31 wild samples of the pneumococcus, a germ that causes pneumonia, the authors observed significant variation in susceptibility between isolates to both AMPs they tested. They also found that clinical isolates were more susceptible to AMPs than were carriage isolates. In plain words, bugs taken from sick people gave way sooner than bugs taken from healthy noses. So the laboratory signal is real, narrow, and tied to the strain in the dish.

Question 4

Does LL-37 do anything against viruses?

Accepted Answer

Two laboratory papers looked at that question. The 2005 eye study records that LL-37 antiviral inhibition of HSV-1 and adenovirus was assessed by direct inactivation assays, which means the peptide and the virus were mixed and the mixture was then tested for infectivity. HSV-1 is the herpes simplex virus behind cold sores, and adenovirus is a common cause of sore red eyes. A 2020 project built new molecules and used LL-37 as its yardstick against respiratory syncytial virus, which is hardest on infants. Two of the seven synthesized peptides, LTP (dendrimer) and SA-35 (linear), used in this study had a stronger antiviral effect than natural peptide LL-37. Notice what that compares: new molecules against LL-37, in cell culture, with no animal and no patient anywhere in the design. The same authors note that the use of natural peptides is limited by low stability in biological media, meaning they break down quickly in body fluids.

Question 5

What is LL-37 used for?

Accepted Answer

In this record LL-37 has two jobs, and neither is a course of care. It serves as a laboratory yardstick for new molecules, as the 2020 antiviral work used it, and it serves as something measured in patients. A 2016 review pushes further than that. Its authors discussed the potency of LL-37 as a therapeutic agent in four systems: immunological, respiratory, gastrointestinal and in the skin, and they analyzed the main molecular pathways dependent on human cathelicidin and related them to specific diseases. They close by arguing that it should be further investigated and developed as a drug with clinical use. Read that last line carefully. A review arguing that a molecule deserves development is a claim about where research might go next, rather than a record of the molecule having been used for anything in a person.

Question 6

What diseases are linked to LL-37?

Accepted Answer

Several, and the link points in both directions. In 17 patients with acne inversa, a long-running skin condition of the armpits and groin, LL-37 was significantly higher in acne inversa lesions compared to non-lesional skin from the same person. In tonsils the arrow flips: the surface epithelium of tonsils from recurrent acute tonsillitis patients showed reduced amounts of antimicrobial peptides human beta-defensins 1 and 3, and LL-37, compared with healthy controls, across 19 patients and five controls. In a 2018 lung study of dermatomyositis, a muscle and skin disease, patients carrying one particular antibody had serum LL-37 of 0.6 plus or minus 1.0 against 0.2 plus or minus 0.2 nanograms per millilitre. And in people with a persistently itchy ear canal, biopsies did not show pronounced expression of human beta-defensin-3 or LL-37 cathelicidin. These are snapshots of people who were already ill, so a high reading in inflamed skin and a low one in a worn tonsil does not tell you which came first.

Question 7

Does killing microbes in a dish mean LL-37 would work in a person?

Accepted Answer

Not by itself, and the reason sits in these same sources. No study among the research behind this page gave LL-37 to a person with an infection, so the question has never been put to the test. What a dish leaves out is the rest of the body, and two papers in this record show exactly what the rest of the body does. In a 2025 experiment, proteins from a yeast selectively degraded key host antimicrobial peptides, including LL-37 cathelicidin, by cutting the peptide at particular links in its chain. In a 2011 culture experiment, cholesterol-grown bacterial cells were substantially more resistant, over 100-fold, to nine agents, and those nine agents included eight antibiotics and LL-37. Add the note from the 2020 antiviral authors about low stability in body fluids and the picture is clear enough. A potency number is measured against microbes in a setting with nothing trying to destroy the peptide, and a living infection is not that setting.

Question 8

Can bacteria and fungi get around LL-37?

Accepted Answer

They can, by at least three separate routes in these sources. Helicobacter pylori, the stomach bacterium, takes cholesterol from its host and coats itself with it. Grown that way it shrugged off twelve antibiotics, six antifungals, and seven antimicrobial peptides tested against it, LL-37 among them. The same paper reports that a mutant unable to do the coating was severely attenuated in gerbils, which ties the trick to real infection in an animal. A yeast uses a blunter method and simply chews the peptide up, and in a caterpillar infection model, an animal test using insect larvae, a pre-treatment with each protease enhanced larval survival. Streptococcus pneumoniae shows a third route, where strains differ among themselves: a 2012 study found that these peptides could flip which strain came out on top when two of them were grown together. Resistance to LL-37, in other words, is ordinary microbial behaviour rather than an exotic case.

Question 9

What is documented about side effects?

Accepted Answer

This is kept to a paragraph, since the safety page carries the detail. Nobody in this record was given LL-37, so there is no account of how a person responded to receiving it. What exists instead is cytotoxicity measured in cell culture, which is the count of how many cells in a dish survive exposure, and the peptide is not inert on that measure. In the 2020 antiviral comparison, four synthesized peptides demonstrated a cytotoxic effect, two of them were even more cytotoxic than LL-37, which attaches a measurable level of damage to mammalian cells to LL-37 itself. The 2005 eye study ran the same kind of check, recording that toxicity of LL-37 to A549 cells was evaluated by a MTT assay, where A549 is a human lung cell line and the assay counts surviving cells. Those are readings from a flask on a bench. The safety page sets out what they do and do not cover.

Question 10

What amounts appear in the published LL-37 work?

Accepted Answer

Concentrations, not doses, and the difference matters more than it sounds. The eye study worked in micrograms per millilitre, with half-effect concentrations between 1.3 and 3.6 for the five bacterial strains it tested. That number describes how much peptide had to be sitting in a defined volume of fluid next to the bacteria. It carries no information about how much material would have to be given to a person to put that concentration anywhere in particular. The only amounts administered to people in this record belong to something else entirely: a vitamin D trial in which participants were allocated to receive placebo, cholecalciferol (vitamin D3 (VD3)) 5600 IU/week (low-dose), or 11 200 IU/week (high-dose) for 6 months. The dosage page collects what the published numbers are and what they are tied to.

Question 11

Is there a published schedule for taking LL-37?

Accepted Answer

There is nothing to build one from. A schedule needs a study that gave a compound on some timetable and then measured what happened, and the human entries here did not give anyone anything. The two completed registry studies are listed as measurements of cathelicidin levels and of cathelicidin expression, in gum fluid, saliva and skin. The nearest thing to a timing question in these sources runs through the body's own production instead. A 2013 hypothesis paper argues that vitamin D induces production of LL-37 (cathelicidin), which has antimicrobial and antiendotoxin properties, and that curcumin also induces LL-37 production through a separate route. Both of those are proposals about raising a person's own supply. Neither tells you anything about when to take a vial of something, and that question has not been asked of anyone in a published study.

Question 12

Does vitamin D raise LL-37, and does that help?

Accepted Answer

The first half of that question has a proposed answer and the second half has a measured one. A 2013 hypothesis paper describes vitamin D as an agent that supports the innate immune system in combating bacterial infections and that induces LL-37 production, with curcumin doing the same through a vitamin D receptor pathway of its own. That is a mechanism argued on paper. The measured half comes from a randomised, double-blind, placebo-controlled trial in 303 children aged 1.5-3.5 years across three Chilean cities. Cathelicidin was tracked there as a secondary outcome, alongside blood vitamin D levels. The trial's headline result was that the investigators did not find a reduced number of acute respiratory infections in this sample. Read the two together. Raising the input that is supposed to raise LL-37 did not lower infection counts in the one trial here that counted them.

Question 13

Is LL-37 approved for anything?

Accepted Answer

No approval record for LL-37 appears among the sources behind this page. The two human studies on the public registry are both marked COMPLETED, and neither carries a phase label, which is the registry's way of saying that neither was testing a candidate medicine on people. One measured levels in smokers and non-smokers with advanced gum disease; the other compared expression in atopic dermatitis and psoriasis. The literature says much the same thing in its own voice: a 2016 review ends by calling for LL-37 to be further investigated and developed as a drug with clinical use, which is the language of a molecule that has not reached that point. That is the regulatory picture in full. It is thinner than the volume of searching around this compound would suggest, and an absent approval record is not the same as a regulator having examined LL-37 and turned it down.

Question 14

How is LL-37 thought to work?

Accepted Answer

On two tracks at once, according to the 2016 review. In addition to being a broad spectrum antibiotic, LL-37 has potent chemotactic and immunomodulatory properties, meaning it also pulls immune cells towards a site and adjusts how loudly they respond. The same review analyzed the main molecular pathways dependent on human cathelicidin, which is how it reaches four different organ systems from one short molecule. Supply is the other half of the mechanism, since the body has to make the peptide before any of that can happen. A 2013 paper puts vitamin D at that switch, describing a route by which it induces production of LL-37 (cathelicidin). And what is made can be unmade: the 2025 yeast work shows enzymes that degraded key host antimicrobial peptides, including LL-37 cathelicidin. Production, action and destruction all sit in the same loop.

LL-37